News
Home/ News
(Filtering posts by category: Patents) - Remove filter
The World Intellectual Property Report 2026 has a simple message: technology is spreading faster than ever — and the advantage now goes to the businesses that can adopt, adapt, and protect faster than their competitors.
The Federal Court has granted AstraZeneca an interlocutory injunction restraining Pharmacor Pty Ltd from launching generic versions of the diabetes medication dapagliflozin. Justice Downes delivered judgment on 16 February 2026, finding in favour of AstraZeneca despite Pharmacor's challenges to the patent's validity and the broader public interest in lower-cost generic medications.
If you’re thinking about patenting an idea, here’s the blunt truth upfront: only genuinely new ideas can be patented. That’s why one of the smartest things you can do before spending serious time or money is to check how others have already solved the same problem.
Australian businesses looking to protect inventions in Europe will soon have a more efficient and cost-effective pathway.
At the start of a new year, many businesses reassess their brands, products and IP portfolios. New launches, market entries and clean-ups are common. What’s often overlooked is the risk sitting in IP that appears abandoned.
For years, Australian innovators have faced uncertainty over whether computer-implemented inventions — software-based systems, digital platforms, or automated processes — can actually be patented. Now, a new Full Court decision has finally brought some clarity — and good news for software and technology businesses.
In a recent decision, Jackman J of the Federal Court handed down a detailed ruling in Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No 3) — a case that dives deep into the complexities of inventive step, novelty, and patent validity in the veterinary pharmaceutical field.
Australia and New Zealand share a common legal heritage — both tracing their patent systems back to the Statute of Monopolies (1623) — but over time, the two jurisdictions have taken different paths. For innovators filing in both countries, understanding these differences can mean the difference between smooth prosecution and costly delays.
Australia’s patent landscape is evolving — and not always in ways that make life easier for innovators. A recent legal trend known as the “relevant range” concept has begun to reshape how courts assess whether a patent specification is sufficiently enabling.
